NR1H4 and alcoholic liver diseases: Among them, the FXR agonist, obeticholic acid, has been tested in different clinical trials, for example, in alcoholic liver disease, in which FXR agonists are thought to decrease the P450 2E1 enzyme responsible for oxidative stress-mediated injury in hepatocytes (Ali et al., 2015).